Documento, Documento-Fibrosis Pulmonar

Factors associated with dose reduction of pirfenidone in patients with idiopathic pulmonary fibrosis: A study based on realworld clinical data

Although pirfenidone slows disease progression in patients with idiopathic pulmonary fibrosis (IPF), in clinical practice, patients often cannot tolerate the recommended dose because of several adverse events. This study aimed to investigate adverse events associated with pirfenidone and factors associated with dose reduction…